BRPI0816554A2 - compostos como antagonistas de receptores de adenosina a1. - Google Patents
compostos como antagonistas de receptores de adenosina a1.Info
- Publication number
- BRPI0816554A2 BRPI0816554A2 BRPI0816554A BRPI0816554A BRPI0816554A2 BR PI0816554 A2 BRPI0816554 A2 BR PI0816554A2 BR PI0816554 A BRPI0816554 A BR PI0816554A BR PI0816554 A BRPI0816554 A BR PI0816554A BR PI0816554 A2 BRPI0816554 A2 BR PI0816554A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- receptor antagonists
- adenosine receptor
- adenosine
- antagonists
- Prior art date
Links
- 229940121359 adenosine receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200702643 | 2007-10-02 | ||
| ES200702643A ES2331220B1 (es) | 2007-10-02 | 2007-10-02 | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
| PCT/IB2008/002556 WO2009044250A1 (en) | 2007-10-02 | 2008-09-30 | New compounds as adenosine a1 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0816554A2 true BRPI0816554A2 (pt) | 2015-11-24 |
| BRPI0816554B1 BRPI0816554B1 (pt) | 2019-04-09 |
| BRPI0816554B8 BRPI0816554B8 (pt) | 2022-08-30 |
Family
ID=40303525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0816554A BRPI0816554B8 (pt) | 2007-10-02 | 2008-09-30 | compostos como antagonistas de receptores de adenosina a1 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8410282B2 (pt) |
| EP (1) | EP2197860B1 (pt) |
| JP (1) | JP5463592B2 (pt) |
| KR (1) | KR101312198B1 (pt) |
| CN (1) | CN101835766B (pt) |
| AT (1) | ATE510829T1 (pt) |
| AU (1) | AU2008306553B2 (pt) |
| BR (1) | BRPI0816554B8 (pt) |
| CA (1) | CA2700526C (pt) |
| CY (1) | CY1112079T1 (pt) |
| DK (1) | DK2197860T3 (pt) |
| EA (1) | EA022473B1 (pt) |
| ES (2) | ES2331220B1 (pt) |
| HR (1) | HRP20110557T1 (pt) |
| MX (1) | MX2010003576A (pt) |
| PL (1) | PL2197860T3 (pt) |
| PT (1) | PT2197860E (pt) |
| SI (1) | SI2197860T1 (pt) |
| WO (1) | WO2009044250A1 (pt) |
| ZA (1) | ZA201002139B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011076734A1 (en) * | 2009-12-21 | 2011-06-30 | Euroscreen S.A. | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
| WO2014106861A1 (en) * | 2013-01-03 | 2014-07-10 | Council Of Scientific & Industrial Research | (4e)-4-(4-substituted benzylideneamino)-2,3-dihydro-3- substituted-2-thioxothiazole-5-carbonitriles as a2ar antagonist and process for preparation thereof |
| JP6434968B2 (ja) | 2013-07-02 | 2018-12-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Rock阻害剤としての三環式ピリド−カルボキサミド誘導体 |
| JP6522602B2 (ja) | 2013-07-02 | 2019-05-29 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Rock阻害剤としての三環式ピリド−カルボキサミド誘導体 |
| ES2578363B1 (es) | 2015-01-22 | 2017-01-31 | Palobiofarma, S.L. | Moduladores de los receptores A3 de adenosina |
| ES2676535B1 (es) * | 2017-01-20 | 2019-04-29 | Palobiofarma Sl | Moduladores de los receptores a3 de adenosina |
| LT3592734T (lt) | 2017-03-06 | 2021-07-26 | Palobiofarma, S.L. | (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska |
| CN107739350B (zh) * | 2017-09-26 | 2020-12-22 | 天津大学 | 一种合成2-氨基噻唑衍生物的方法 |
| BR112021004999A2 (pt) | 2018-09-17 | 2021-06-08 | Yungjin Pharm. Co., Ltd. | composto e método de inibição de cdk7 em um sujeito |
| EP3882240A1 (en) * | 2020-03-16 | 2021-09-22 | Palobiofarma, S.L. | Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid |
| EP3957308A1 (en) * | 2020-08-21 | 2022-02-23 | Palobiofarma, S.L. | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
| CN119039300A (zh) * | 2024-08-29 | 2024-11-29 | 上海信诺维生物医药有限公司 | 吡唑并嘧啶类化合物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050004134A1 (en) * | 2001-11-08 | 2005-01-06 | Hideo Tsutsumi | Thiazole derivative and pharmaceutical use thereof |
| KR101010905B1 (ko) * | 2002-01-18 | 2011-01-25 | 아스텔라스세이야쿠 가부시키가이샤 | 2-아실아미노티아졸 유도체 또는 그 염 |
| NZ570835A (en) * | 2006-03-08 | 2011-11-25 | Achillion Pharmaceuticals Inc | Substituted aminothiazole derivatives with anti-HCV activity |
| WO2007116106A1 (es) * | 2006-04-12 | 2007-10-18 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina |
-
2007
- 2007-10-02 ES ES200702643A patent/ES2331220B1/es not_active Expired - Fee Related
-
2008
- 2008-09-30 EA EA201000393A patent/EA022473B1/ru not_active IP Right Cessation
- 2008-09-30 SI SI200830350T patent/SI2197860T1/sl unknown
- 2008-09-30 ES ES08835072T patent/ES2366075T3/es active Active
- 2008-09-30 AT AT08835072T patent/ATE510829T1/de active
- 2008-09-30 PT PT08835072T patent/PT2197860E/pt unknown
- 2008-09-30 WO PCT/IB2008/002556 patent/WO2009044250A1/en not_active Ceased
- 2008-09-30 MX MX2010003576A patent/MX2010003576A/es active IP Right Grant
- 2008-09-30 CN CN2008801126777A patent/CN101835766B/zh active Active
- 2008-09-30 EP EP08835072A patent/EP2197860B1/en active Active
- 2008-09-30 HR HR20110557T patent/HRP20110557T1/hr unknown
- 2008-09-30 BR BRPI0816554A patent/BRPI0816554B8/pt active IP Right Grant
- 2008-09-30 US US12/679,941 patent/US8410282B2/en active Active
- 2008-09-30 CA CA2700526A patent/CA2700526C/en active Active
- 2008-09-30 AU AU2008306553A patent/AU2008306553B2/en not_active Ceased
- 2008-09-30 JP JP2010527561A patent/JP5463592B2/ja active Active
- 2008-09-30 PL PL08835072T patent/PL2197860T3/pl unknown
- 2008-09-30 KR KR1020107008768A patent/KR101312198B1/ko active Active
- 2008-09-30 DK DK08835072.3T patent/DK2197860T3/da active
-
2010
- 2010-03-25 ZA ZA2010/02139A patent/ZA201002139B/en unknown
-
2011
- 2011-08-22 CY CY20111100805T patent/CY1112079T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008306553A1 (en) | 2009-04-09 |
| PL2197860T3 (pl) | 2011-09-30 |
| PT2197860E (pt) | 2011-08-26 |
| EP2197860B1 (en) | 2011-05-25 |
| KR101312198B1 (ko) | 2013-09-27 |
| BRPI0816554B8 (pt) | 2022-08-30 |
| AU2008306553B2 (en) | 2011-06-09 |
| CN101835766A (zh) | 2010-09-15 |
| ZA201002139B (en) | 2011-06-29 |
| EA201000393A1 (ru) | 2010-08-30 |
| BRPI0816554B1 (pt) | 2019-04-09 |
| CA2700526A1 (en) | 2009-04-09 |
| ES2331220A1 (es) | 2009-12-23 |
| JP2010540615A (ja) | 2010-12-24 |
| US20100311703A1 (en) | 2010-12-09 |
| ES2331220B1 (es) | 2010-09-23 |
| WO2009044250A1 (en) | 2009-04-09 |
| DK2197860T3 (da) | 2011-08-15 |
| US8410282B2 (en) | 2013-04-02 |
| JP5463592B2 (ja) | 2014-04-09 |
| HRP20110557T1 (hr) | 2011-09-30 |
| CN101835766B (zh) | 2013-09-25 |
| ES2366075T3 (es) | 2011-10-17 |
| SI2197860T1 (sl) | 2011-09-30 |
| EA022473B1 (ru) | 2016-01-29 |
| EP2197860A1 (en) | 2010-06-23 |
| ATE510829T1 (de) | 2011-06-15 |
| MX2010003576A (es) | 2010-04-22 |
| KR20100058653A (ko) | 2010-06-03 |
| CY1112079T1 (el) | 2015-11-04 |
| CA2700526C (en) | 2014-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0816554A2 (pt) | compostos como antagonistas de receptores de adenosina a1. | |
| BRPI0909157A2 (pt) | compostos heterocíclicos como antagonistas de receptores de adenosina | |
| BRPI0716936A2 (pt) | derivados de adenosina como antigonistas de receptor de a2a | |
| CR10249A (es) | Compuestos de amino- pirimidina 2,6-sistituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2 | |
| EP2350060A4 (en) | Melanocortin receptor AGONISTS | |
| BRPI0821141A2 (pt) | Derivados de heteroarila como antagonistas do receptor de orexina | |
| BRPI0911542A2 (pt) | compostos de quinuclina como ligantes de receptor de receptor de acetilcolina alfa-7-nicotínica | |
| BRPI0717937A2 (pt) | Compostos de pirazona como antagonistas do receptor mineralocorticóide | |
| BRPI0717023A2 (pt) | Tiazol pirazolopirimidina como antagonistas do receptor de crf1 | |
| BRPI0818578A2 (pt) | Derivados de purina como ligantes receptores de adenosina a1 | |
| DK2089382T3 (da) | Substituerede diazepan-forbindelser som orexin-receptor-antagonister | |
| BRPI0913930A2 (pt) | antagonistas de receptores de prostaglandinas d2 | |
| BRPI0810462A2 (pt) | Derivados de quinolina-carboxamida como antagonistas de p2y12 | |
| EP2349270A4 (en) | 2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS | |
| BRPI0813768A2 (pt) | Derivados de benzazepina úteis como antagonistas de vasopressina | |
| BRPI0907364A2 (pt) | Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina | |
| BRPI0919844A2 (pt) | compostos de azaindazol como antagonistas do receptor ccr1 | |
| BRPI0815797A2 (pt) | Compostos 8-azabiciclo[3.2.1]octil-2-hidroxibanzamida como antagonistas de receptor opióide mu | |
| BRPI0820805A2 (pt) | Antagonista do receptor de mineralocorticóides derivados da 6h-di-benzo[b,e]oxepina | |
| BRPI0817061A2 (pt) | Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3 | |
| BRPI0814806A2 (pt) | Pirazinas substituídas como antagonistas de cb1 | |
| EP2379510A4 (en) | quinazolinone | |
| BRPI0720078A2 (pt) | 2-aminoquinolinas como antagonistas de receptores de 5-ht(5a) | |
| BRPI0814767A2 (pt) | Derivados de monoamida como antagonistas do receptor de orexina | |
| BRPI0809641A2 (pt) | Pirimidinil-piperazinas úteis como ligantes do receptor d3/d2hu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2518 DE 09/04/2019 QUANTO AO INVENTOR. |